Authum Investment & Infrastructure Limited Schedules Board Meeting on May 26, 2026 to Approve FY26 Audited Financial Results

Authum Investment & Infrastructure Limited has notified the stock exchanges of a forthcoming Board of Directors meeting, scheduled for Tuesday, May 26, 2026. The intimation was filed on May 19, 2026, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The board meeting has been convened to transact the following key business:

Consideration and approval of the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended March 31, 2026, along with the Audited Report (Standalone & Consolidated)

Any other item with the permission of the Chairman of the Board, if any

The following table summarises the key details of the scheduled board meeting:

Parameter: Details Meeting Date: Tuesday, May 26, 2026 Filing Date: May 19, 2026 Regulatory Reference: Regulation 29, SEBI (LODR) Regulations, 2015 Financial Results Period: Quarter and year ended March 31, 2026 Results Type: Standalone & Consolidated (Audited)

Trading Window Closure

In continuation of the company's earlier communication dated March 25, 2026, and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended by the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, along with the Company's Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the equity shares of the company has remained closed from Wednesday, April 01, 2026.

The trading window will reopen 48 hours after the conclusion of the Board Meeting scheduled on May 26, 2026. This restriction applies to all Directors, designated persons, and their immediate relatives.

The intimation was signed by Dipyanti Jaiswar, Company Secretary & Compliance Officer, from Mumbai, on May 19, 2026.

Authum inv & infr has announced a significant employee benefit initiative through the grant of stock options under its newly established Employee Stock Option Scheme 2025. The company's Nomination and Remuneration Committee approved the grant of 19,80,000 stock options to eligible employees on April 17, 2026, demonstrating the organization's commitment to employee participation in its growth trajectory.

Stock Option Grant Details

The comprehensive stock option grant encompasses several key parameters designed to align employee interests with company performance:

Parameter: Details Total Options Granted: 19,80,000 Exercise Price: Rs. 300 per share Face Value per Share: Rs. 1 Scheme Name: ESOP 2025 Grant Date: April 17, 2026

Vesting and Exercise Framework

The stock options follow a structured vesting schedule designed to promote long-term employee retention and performance. The vesting framework includes:

Vesting Schedule:

Year 1: 25% of allocated options

Year 2: 25% of allocated options

Year 3: 25% of allocated options

Year 4: 25% of allocated options

Exercise Parameters:

Options can be exercised within a maximum period of 5 years from the vesting date

Each option converts to one equity share with face value of Rs. 1

No lock-in period applicable post-exercise

Regulatory Compliance and Administration

The stock option scheme operates under strict regulatory oversight and compliance frameworks as disclosed under Regulation 30 of SEBI LODR:

Compliance Aspect: Details Regulatory Framework: SEBI (SBEB) Regulations, 2021 Disclosure Requirements: SEBI LODR Regulation 30 Administration: Nomination and Remuneration Committee Scheme Compliance: Fully compliant with applicable regulations SEBI Circular Reference: SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123

The scheme administration will be managed by the company's Nomination and Remuneration Committee, ensuring proper governance and oversight of the option grants. The committee retains authority to determine exercise periods and communicate relevant details to grantees within the maximum five-year exercise window.

Financial Impact and Structure

While immediate financial impacts remain to be determined as options have not yet been exercised, the scheme establishes a clear framework for future employee participation in company equity. The exercise price of Rs. 300 per share provides employees with potential upside participation based on the company's future performance and stock price appreciation.

The disclosure indicates that aspects such as money realized from option exercises, total shares arising from exercises, and diluted earnings per share calculations will be reported as options are exercised over the vesting period. This structured approach ensures transparency and regulatory compliance throughout the scheme's implementation.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.